Regulatory filings underway for a third indication for darolutamide in prostate cancer, for finerenone in a common form of heart failure, and acoramidis in transthyretin amyloid
Acquisition adds potential best-in-class disease-modifying therapy for Alzheimer's disease
Attruby is the first and only approved product with a label specifying near-complete stabilization of TTR
Strengthening focus in Alzheimer's disease and neuroscience pipeline
Financing includes new funding from leading global organizations Eli Lilly and Company and EDBI
Jubilant's Radiopharma Business to expand positron emission tomography radiopharmacy network
This marks the first FDA approval of an AI-based brain disorder analysis solution from Korea
US FDA approval based on NEURO-TTRansform Phase III results
The positive safety review from the DSMB enables the trial to move forward as planned, with an estimated completion date in December 2023
ZYIL1 is a novel oral small molecule NLRP3 inhibitor which has demonstrated CSF penetration in non-human primates
Subscribe To Our Newsletter & Stay Updated
